DSHNHL R3 is a randomized clinical phase II study. The main objective is to estimate the
efficacy of rituximab as a prophylactic medication for prevention of
graft-versus-host-disease after allogeneic peripheral stem cell transplantation in patients
with a high risk relapse of aggressive B-cell Non-Hodgkin's lymphoma. The most important
secondary objective is to estimate the efficacy of allogeneic stem cell transplantation in
this clinical situation.
Phase:
Phase 2
Details
Lead Sponsor:
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Collaborators:
German High-Grade Non-Hodgkin's Lymphoma Study Group University Hospital Goettingen